Labnovation Spotlights HbA1c and Alzheimer’s Blood-Based Testing Solutions

At booth 2469, the company is presenting a complete HbA1c testing portfolio alongside a blood-based approach intended to support earlier and more accessible assessment of Alzheimer’s disease.

The HbA1c portfolio includes three platforms designed for testing environments ranging from high-throughput laboratories to point-of-care settings. The systems are intended to provide laboratories with different combinations of speed, capacity, precision, and workflow flexibility for diabetes diagnosis and long-term glycemic monitoring.

For laboratories processing larger testing volumes, the LD-600 delivers HbA1c results in approximately 70 seconds per test, with a stated coefficient of variation of 1% or less. The system is positioned as the high-throughput option within the company’s ADLM showcase.

The compact LD-560 is designed for laboratories with moderate sample volumes and provides results in approximately 90 seconds per test, also with a stated coefficient of variation of 1% or less. The automated analyzer uses high-performance liquid chromatography for HbA1c measurement.

Completing the portfolio is the LD-100, a point-of-care-ready analyzer that generates results in under three minutes with a stated coefficient of variation of 2.5% or less. Its compact format is intended to extend HbA1c testing beyond centralized laboratories to smaller clinical and decentralized care settings.

Labnovation is additionally presenting a blood-based testing solution for Alzheimer’s disease. The company introduces the approach as a noninvasive and accessible option that uses a simple blood draw to support earlier detection.